FINATE 160® Tablets
Composition:
FINATE 160®
- Each film coated tablet contains:
- Fenofibrate I.P. …………………………………………………………………………. 160 mg (in micronised form)
- Excipients ……………………………………………………………………………………. q.s.
- Colour: Titanium Dioxide I.P.
Description
- In metabolic syndrome, insulin resistance, and Type 2 Diabetes, lipid metabolism is disrupted—leading to high triglycerides, low HDL, and small, dense LDL, which together increase cardiovascular risk.
- FINATE 160®, containing Fenofibrate, activates PPAR-α, promoting:
1).Triglyceride breakdown by increasing lipoprotein lipase activity
2).Reduced apo C-III (an inhibitor of lipoprotein lipase)
3).Increased apo C-II, enhancing lipase activity
4).Conversion of small, dense LDL to larger, less atherogenic particles
5).Increased HDL-C and synthesis of apoA-I and apoA-II
6).These actions improve the overall lipid profile, especially in high-risk patients with diabetes or insulin resistance.
Indications
- In Hypertriglyceridemia FINATE 160® is indicated as adjunctive therapy to diet for treatment of adult patients with severe hyper triglyceridaemia.
- In the treatment of type IIa, Ilb, III, IV and V hyperlipidaemia uncontrolled by diet therapy
Dosage
- Patients should be placed on an appropriate lipid-lowering diet before receiving FINATE 160®, and should continue this diet during the treatment with FINATE 160®. FINATE 160® tablets can be given without regard to meals. Lipid levels should be monitored periodically and consideration should be given to reducing the dosage of FINATE 160® if the lipid levels fall significantly below the targeted range.